Stock index futures rose on Wednesday as investors geared up for Nvidia’s ( NVDA) fourth-quarter results slated to be out after the market close.

Baidu faces stagnant search MAUs and falling ARPU, betting on AI infrastructure, apps and Kunlunxin IPO for growth. Learn more about BIDU stock here.

Stocks struggled for direction coming out of the long weekend. The Nasdaq composite led early losses, dropping more than 1% in Tuesday morning trading, before reversing course. All three major indexes ...

The Business Services group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Agora, Inc. Sponsored ADR (API) is a stock that can ...

Comprehensive Python API for Google NotebookLM. Full programmatic access to NotebookLM's features—including capabilities the web UI doesn't expose—from Python or the command line. 📚 Research ...

(RTTNews) - Stocks have seen considerable volatility over the course of the trading day on Friday, with the major averages swinging wildly back and forth across the unchanged line following the steep ...

CEO Brian Bird highlighted major strategic achievements, including the announcement of an all-stock Merger of Equals with Black Hills Corporation, closing of acquisitions for Avista and Puget Colstrip ...

(RTTNews) - European stocks were mixed on Friday despite a sell-off on Wall Street overnight amid growing concerns about artificial-intelligence disruptions. The pan-European Stoxx 600 was marginally ...

Here are the top stories to read ahead of Tuesday's trading: ...

Stocks dropped sharply Thursday as AI concerns came to the surface once again. The Nasdaq composite led major benchmarks lower with a loss of 2%. The Dow industrials retreated below 50000, down 669 ...

The S&P 500 closed barely above the flatline on Friday as a key consumer inflation report that came in slightly lighter than expected failed to spark a substantial rally. The broad market index added ...

BridgeBio Pharma Inc. (NASDAQ:BBIO) stock is surging on Thursday and nearing the upper end of its 52-week range of $28.33-$84.94, according to Benzinga Pro data. The biopharmaceutical company focused ...